TattersallJ.E., DoyleS., GreenwoodR.N., FarringtonK.Kinetic modeling and under dialysis in CAPD patients.Nephrol Dial Transplant1993; 8: 535–8.
2.
BlakeP.G.Targets in CAPD and APD prescription.Perit Dial Int1996; 16(Suppl 1): S143–6.
3.
BlakeP.G.A critique of the Canada/USA (CANUSA) peritoneal dialysis study.Perit Dial Int1996; 16: 243–5.
4.
National Kidney Foundation.Clinical practice guidelines and clinical practice recommendations 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy, vascular access.Am J Kidney Dis2006; 48(Suppl 1): S1–322.
5.
WangA.Y., LaiK.N.The importance of residual renal function in dialysis patients.Kidney Int2006; 69: 1726–32.
6.
BargmanJ.M., ThorpeK.E., ChurchillD.N.Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study.J Am Soc Nephrol2001; 12: 2158–62.
7.
SzetoC.C., WongT. Y., LeungC.B., WangA.Y., LawM.C., LuiS.F.Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients.Kidney Int2000; 58: 400–7.
8.
MaiorcaR., BrunoriG., ZubaniR., CancariniG.C., ManiliL., CameriniC.Predictive value of dialysis adequacy and nutritional indices for mortality and morbidity in CAPD and HD patients. A longitudinal study.Nephrol Dial Transplant1995; 10: 2295–305.
9.
Diaz-BuxoJ.A., LowrieE.G., LewN.L., ZhangS.M., ZhuX., LazarusJ.M.Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance.Am J Kidney Dis1999; 33: 523–34.
10.
RoccoM., SoucieJ.M., PastanS., McClellanW.M.Peritoneal dialysis adequacy and risk of death.Kidney Int2000; 58: 446–57.
11.
Canada-USA (CANUSA) Peritoneal Dialysis Study Group.Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes.J Am Soc Nephrol1996; 7: 198–207.
12.
PaniaguaR., AmatoD., VoneshE.F., Correa-RotterR., RamosA., MoranJ.Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial.J Am Soc Nephrol2002; 13: 1307–20.
13.
Witko-SarsatV., FriedlanderM., NguyenK.T., Capeillère-BlandinC., NguyenA.T., CanteloupS.Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure.J Immunol1998; 161: 2524–32.
14.
ShinS.K., NohH., KangS.W., SeoB.J., LeeI.H., SongH.Y.Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients.Perit Dial Int1999; 19: 138–42.
15.
WangA.Y., SeaM.M., TangN., SandersonJ.E., LuiS.F., LiP.K.Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients.J Am Soc Nephrol2004; 15: 3134–43.
16.
VenkataramanV., NolphK.D.Preservation of residual renal function—an important goal.Perit Dial Int2000; 20: 392–5.
17.
MedcalfJ.F., HarrisK.P., WallsJ.Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis.Kidney Int2001; 59: 1128–33.
18.
MoistL.M., PortF.K., OrzolS.M., YoungE.W., OstbyeT., WolfeR.A.Predictors of loss of residual renal function among new dialysis patients.J Am Soc Nephrol2000; 11: 556–64.
19.
LiP.K., ChowK.M., WongT. Y., LeungC.B., SzetoC.C.Effects of an angiotensin converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis: a prospective randomized study.Ann Intern Med2003; 139: 105–12.
20.
CancariniG.C., BrunoriG., CameriniC., BrasaS., ManiliL., MaiorcaR.Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis.Perit Dial Bull1986; 6: 77–9.
21.
LuiS.L., ChengS.W., NgF., NgS. Y., WanK.M., YipT.Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function.Kidney Int2005; 68: 2375–80.
22.
BakerR.J., SeniorH., ClemengerM., BrownE.A.Empirical aminoglycosides for peritonitis do not affect residual renal function.Am J Kidney Dis2003; 41: 670–5.
23.
SuzukiH., KannoY., SugaharaS., OkadaH., NakamotoH.Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.Am J Kidney Dis2004; 43: 1056–64.
24.
GoldsteinA., KligerA.S., FinkelsteinF.O.Recovery of renal function and the discontinuation of dialysis in patients treated with continuous peritoneal dialysis.Perit Dial Int2003; 23: 151–6.
BellomoR.Defining, quantifying, and classifying acute renal failure.Crit Care Clin2005; 21: 223–37.
27.
SekkarieM.A., PortF.K., WolfeR.A., GuireK., HumphrysR., Van AmburgG.Recovery from end-stage renal disease.Am J Kidney Dis1990; 15: 61–5.
28.
RottembourgJ.Residual renal function and recovery of renal function in patients treated by C APD.Kidney Int Suppl1993; 40: S106–10.
29.
CravenA.M.S., HawleyC.M., McDonaldS.P., RosmanJ.B., BrownF.G., JohnsonD.W.Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis.Perit Dial Int2007; 27: 184–91.
